GTP binding controls complex formation by the human ROCO protein MASL1
FEBS JOURNAL
Authors: Dihanich, Sybille; Civiero, Laura; Manzoni, Claudia; Mamais, Adamantios; Bandopadhyay, Rina; Greggio, Elisa; Lewis, Patrick A.
Abstract
The human ROCO proteins are a family of multi-domain proteins sharing a conserved ROC-COR supra-domain. The family has four members: leucine-rich repeat kinase 1 (LRRK1), leucine-rich repeat kinase 2 (LRRK2), death-associated protein kinase 1 (DAPK1) and malignant fibrous histiocytoma amplified sequences with leucine-rich tandem repeats 1 (MASL1). Previous studies of LRRK1/2 and DAPK1 have shown that the ROC (Ras of complex proteins) domain can bind and hydrolyse GTP, but the cellular consequences of this activity are still unclear. Here, the first biochemical characterization of MASL1 and the impact of GTP binding on MASL1 complex formation are reported. The results demonstrate that MASL1, similar to other ROCO proteins, can bind guanosine nucleotides via its ROC domain. Furthermore, MASL1 exists in two distinct cellular complexes associated with heat shock protein 60, and the formation of a low molecular weight pool of MASL1 is modulated by GTP binding. Finally, loss of GTP enhances MASL1 toxicity in cells. Taken together, these data point to a central role for the ROC/GTPase domain of MASL1 in the regulation of its cellular function.
Overexpression of translocation-associated fusion genes of FGFR1, MYC, NPM1, and DEK, but absence of the translocations in acute myeloid leukemia. A microarray analysis
HAEMATOLOGICA
Authors: Larramendy, ML; Niini, T; Elonen, E; Nagy, B; Ollila, J; Vihinen, M; Knuutila, S
Abstract
Background and Objectives. Translocation-associated gene fusions are well recognized in acute myeloid leukemia. Other molecular genetic changes are less well known. The novel cDNA technology has opened the avenue to large-scale gene expression analysis. Our aim was to perform cDNA microarray analysis of acute myeloid leukemia (AML). Design and Methods. We performed cDNA microarray analysis using the Clontech hematology filter (containing 406 genes) on 15 patients to study gene expression profiling in AML. As reference, we used whole bone marrow from 5 healthy donors. Results. Our results revealed 50 differentially expressed genes in at least 3 out of 15 patients. Twenty-two genes were upregulated (ratio greater than or equal to 4), whereas 28 genes were downregulated (ratio less than or equal to 0.25). All but one of the 13 genes tested by real-time polymerase chain reaction (PCR) showed the same expression profiles. Among the overexpressed genes, several were those earlier associated with chromosomal, translocations,,and gene fusions. These genes were FGFR1, MYC, NPM1 DEC, and BCL2. The expression of two upregulated genes HOXA4 and CSF1R, was significantly higher in patients with a white blood cell count higher than 36x10(9)/L cells. In patients whose white blood cell,count was higher than 100X10(9)/L cells, both CLC and GRN were significantly underexpressed, whereas HOXA4 and DAPK1 were overexpressed. FGFR1 and CAMLG were more frequently significantly overexpressed in patients with CD56 immunophenoytpe. Interpretation and Conclusions. Clinical and prognostic significance of differential gene expression should be studied with a larger series of patients by using other techniques, as quantitaltive real-time PCR. (C) 2002 Ferrata Storti Foundation.